Vor Biopharma Financial Statements
NASDAQ: VORHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
19.90+0.77 (+4.03%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Vor Biopharma revenue and earnings
Vor Biopharma reported a net loss of $696.0 million, compared with a loss of $116.9 million a year earlier. Diluted earnings per share came in at -$70.50.
Summary generated from market data by MetaCap's automated system. Methodology
Vor Biopharma income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Operating Expenses | 371.64M | 121.19M | 126.04M | 93.42M | 69.02M | 43.37M |
| Research & Development | 321.53M | 93.31M | 94.31M | 64.55M | 47.53M | 31.62M |
| Operating Income | -371.64M | -121.19M | -126.04M | -93.42M | -69.02M | -43.37M |
| Other Income (Expense) | -324.34M | 4.27M | 8.17M | 1.32M | 119.00K | 29.00K |
| Net Income | -695.98M | -116.91M | -117.86M | -92.09M | -68.90M | -43.34M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| EPS (Basic) | -70.50 | -34.03 | -1.75 | -2.33 | -2.10 | -230.57 |
| EPS (Diluted) | -70.50 | -34.03 | -1.75 | -2.33 | -2.10 | -230.57 |
| Shares Outstanding (Basic) | 9.87M | 3.44M | 67.19M | 39.55M | 33.43M | 213.66K |
| Shares Outstanding (Diluted) | 9.87M | 3.44M | 67.19M | 39.55M | 33.43M | 213.66K |
| EBITDA | -368.75M | -117.66M | -122.54M | -90.89M | -67.58M | -42.76M |
This table shows 6 annual periods of Vor Biopharma's income statement, from FY 2025 back to FY 2020, across 10 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow VOR's reporting calendar. What is a income statement?